ArticlebioRxiv : the preprint server for biology2025
Profiling a large HIV-1 elite neutralizer cohort reveals remarkable CD4bs bNAb for HIV-1 prevention and therapy.
Abstract readPreprint
In one paragraph
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
49 authors.
Lutz GieselmannLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Andrew T DeLaitschDivison of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Malena RohdeLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Henning GruellLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.ORCID 0000-0002-0725-7138
Christoph KreerLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.ORCID 0000-0002-9140-9850
Meryem Seda ErcanogluLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Harry B GristickDivison of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.ORCID 0000-0002-1957-2821
Philipp SchommersLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Elvin AhmadovLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Caelan RadfordBasic Sciences Division, Fred Hutch Cancer Center, Seattle, WA, USA.
Andrea MazzoliniLaboratoire de Physique de l'Ecole Normale Supérieure, CNRS, Paris Sciences and Lettres University, Sorbonne Université, and Université Paris-Cité, 75005 Paris, France.
Lily ZhangVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA.
Anthony P WestDivison of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Johanna WorczinskiLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Anna MomotLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Maren L ReichweinLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Jacqueline KnüferLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Ricarda StumpfLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Nonhlanhla N MkhizeSAMRC Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Haajira KaldineSAMRC Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Sinethemba BhebheSAMRC Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Sharvari DeshpandeVir Biotechnology, San Francisco, CA, United States.
Frederico GiovannoniVir Biotechnology, San Francisco, CA, United States.
Erin StefanuttiVir Biotechnology, San Francisco, CA, United States.
Fabio BenigniVir Biotechnology, San Francisco, CA, United States.
Colin Havenar-DaughtonVir Biotechnology, San Francisco, CA, United States.
Davide CortiVir Biotechnology, San Francisco, CA, United States.
Arne KroidlInstitute of Infectious Diseases and Tropical Medicine, University of Hospital of Munich (LMU), Munich, Germany.
Anurag AdhikariDepartment of Infection and Immunology, Kathmandu Research Institute for Biological Sciences, Lalitpur 44700, Nepal.
Aubin J NanfackChantal BIYA International Reference Centre for research on HIV/AIDS Prevention and Management, Yaoundé, Cameroon.
Georgia E AmbadaChantal BIYA International Reference Centre for research on HIV/AIDS Prevention and Management, Yaoundé, Cameroon.
Ralf DuerrDepartment of Microbiology, New York University School of Medicine, New York City, NY, USA.
Lucas MagangaMbeya Medical Research Centre, National Institute for Medical Research, Mbeya, Tanzania.ORCID 0000-0002-5797-1364
Wiston WilliamMbeya Medical Research Centre, National Institute for Medical Research, Mbeya, Tanzania.
Nyanda E NtinginyaMbeya Medical Research Centre, National Institute for Medical Research, Mbeya, Tanzania.
Timo WolfDepartment for Infectious Diseases, Centre of Internal Medicine II, University Hospital Frankfurt, 60590 Frankfurt am Main, Germany.
Christof GeldmacherInstitute of Infectious Diseases and Tropical Medicine, University of Hospital of Munich (LMU), Munich, Germany.
Michael HoelscherInstitute of Infectious Diseases and Tropical Medicine, University of Hospital of Munich (LMU), Munich, Germany.
Clara LehmannGerman Center for Infection Research, Partner Site Bonn-Cologne, 50931 Cologne, Germany.
Penny L MooreSAMRC Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Thierry MoraLaboratoire de Physique de l'Ecole Normale Supérieure, CNRS, Paris Sciences and Lettres University, Sorbonne Université, and Université Paris-Cité, 75005 Paris, France.
Aleksandra M WalczakLaboratoire de Physique de l'Ecole Normale Supérieure, CNRS, Paris Sciences and Lettres University, Sorbonne Université, and Université Paris-Cité, 75005 Paris, France.
Peter B GilbertVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA.
Nicole A Doria-RoseVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Yunda HuangVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA.
Jesse D BloomBasic Sciences and Computational Biology, Fred Hutchinson Cancer Research Center, Seattle, USA.ORCID 0000-0003-1267-3408
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Pamela J BjorkmanDivison of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Florian KleinLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
Funding
Stuctural basis of bNab activityP01AI100148 · NIAID · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI Pamela J Bjorkman · 2013 to 2026
$43.3MCHEETAH Center for the Structural Biology of HIV Infection, Restriction, and Viral DynamicsU54AI170856 · NIAID · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI WALTHER H MOTHES · 2022 to 2026
$34.4MDefining the mechanisms of HIV resistance to bNAbs in humansU01AI169385 · NIAID · ROCKEFELLER UNIVERSITY · PI Marina Caskey · 2022 to 2026
$7.8MComplete mapping of immune selection from antibodies to HIVR01AI140891 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BLOOM, JESSE D · 2019 to 2024
$2.4MGates Foundation INV-002143Gates Foundation INV-036842NIAID NIH HHS P01 AI100148NIAID NIH HHS R01 AI140891NIAID NIH HHS U01 AI169385NIAID NIH HHS U54 AI170856
Abstract
Administration of HIV-1 neutralizing antibodies can suppress viremia and prevent infection
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.